Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity against prevalent SARS-CoV-2 variants
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity against prevalent SARS-CoV-2 variants
Authors
Keywords
COVID-19, Delta, B.1.617.2, immunity, heterologous vaccination
Journal
EBioMedicine
Volume 75, Issue -, Pages 103761
Publisher
Elsevier BV
Online
2021-12-18
DOI
10.1016/j.ebiom.2021.103761
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine induced sera
- (2021) Daming Zhou et al. CELL
- Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials
- (2021) Merryn Voysey et al. LANCET
- Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine
- (2021) Florian Krammer et al. NEW ENGLAND JOURNAL OF MEDICINE
- SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies
- (2021) Markus Hoffmann et al. CELL
- Antibody-mediated procoagulant platelets in SARS-CoV-2- vaccination associated immune thrombotic thrombocytopenia
- (2021) Karina Althaus et al. HAEMATOLOGICA
- Characterization of the SARS-CoV-2 Neutralization Potential of COVID-19–Convalescent Donors
- (2021) Bernd Jahrsdörfer et al. JOURNAL OF IMMUNOLOGY
- Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study
- (2021) Eleftheria Vasileiou et al. LANCET
- Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data
- (2021) Eric J Haas et al. LANCET
- Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data
- (2021) Robert H Shaw et al. LANCET
- Author Correction: Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses
- (2021) Jordan R. Barrett et al. NATURE MEDICINE
- Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection
- (2021) David S. Khoury et al. NATURE MEDICINE
- Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant
- (2021) Shabir A. Madhi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population based cohort study
- (2021) Anton Pottegård et al. BMJ-British Medical Journal
- A global database of COVID-19 vaccinations
- (2021) Edouard Mathieu et al. Nature Human Behaviour
- Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial
- (2021) Xinxue Liu et al. LANCET
- Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination
- (2021) Emma C Wall et al. LANCET
- Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial
- (2021) Alberto M Borobia et al. LANCET
- Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization
- (2021) Delphine Planas et al. NATURE
- Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans
- (2021) Galit Alter et al. NATURE
- Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination
- (2021) Tina Schmidt et al. NATURE MEDICINE
- Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination
- (2021) Joana Barros-Martins et al. NATURE MEDICINE
- Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants
- (2021) Lingshu Wang et al. SCIENCE
- Two doses of the SARS-CoV-2 BNT162b2 vaccine enhance antibody responses to variants in individuals with prior SARS-CoV-2 infection
- (2021) Richard A. Urbanowicz et al. Science Translational Medicine
- SARS-CoV-2 variant B.1.617 is resistant to bamlanivimab and evades antibodies induced by infection and vaccination
- (2021) Markus Hoffmann et al. Cell Reports
- SARS-CoV-2 vaccines for all but a single dose for COVID-19 survivors
- (2021) Matthew Frieman et al. EBioMedicine
- Immunogenicity and efficacy of heterologous ChAdOx1–BNT162b2 vaccination
- (2021) Bruno Pozzetto et al. NATURE
- SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor
- (2020) Markus Hoffmann et al. CELL
- Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
- (2020) Pedro M Folegatti et al. LANCET
- 3M-052, a synthetic TLR-7/8 agonist, induces durable HIV-1 envelope–specific plasma cells and humoral immunity in nonhuman primates
- (2020) Sudhir Pai Kasturi et al. Science Immunology
- Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19
- (2020) Takuya Sekine et al. CELL
- Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity
- (2020) Carolyn Rydyznski Moderbacher et al. CELL
- Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK
- (2020) Merryn Voysey et al. LANCET
- Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial
- (2020) Maheshi N Ramasamy et al. LANCET
- T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial
- (2020) Katie J. Ewer et al. NATURE MEDICINE
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
- (2020) Fernando P. Polack et al. NEW ENGLAND JOURNAL OF MEDICINE
- IgA dominates the early neutralizing antibody response to SARS-CoV-2
- (2020) Delphine Sterlin et al. Science Translational Medicine
- Functional analysis of potential cleavage sites in the MERS-coronavirus spike protein
- (2018) Hannah Kleine-Weber et al. Scientific Reports
- A Vesicular Stomatitis Virus Replicon-Based Bioassay for the Rapid and Sensitive Determination of Multi-Species Type I Interferon
- (2011) Marianne Berger Rentsch et al. PLoS One
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started